I'm wondering if the "fantastic position we're going to be in post-COVID" is leaking... $199!
D
it's goin down because the big boys want to get in
Y
Inari Medical is up 9.22% to 83.00
Y
Inari Medical is down 9.65% to 56.53
Y
Inari Medical is down 9.16% to 64.78
Y
Inari Medical reached a 52 Week low at 62.69
Y
Inari Medical is down 8.53% to 76.27
D
There is 50 M outstanding shares, so 2 M is not much of dilution. They are profitable, they have 179 M cash and only 29 M debt. Why this offering, they do not need money? It could be some acquisition. Any second offering with intention to grow business is a wise decision.
Y
Inari Medical reached a 52 Week low at 60.64
Y
Inari Medical is up 8.13% to 94.00
K
now I know why Penumbra is the better stock ... this is going down to $50 with the dilution. No wonder there was something fishy with the runup to the high 90s.
G
Investing right now will be at every wise individual list. In few weeks you'll be ecstatic with the decision you made today
A
amazing, blew it out of the water.
- revenue 144% over last year - 2x forecast for this year - earnings crossed over to positive - huge margins + entering new European market + 2 new products
I think we'll see $199 before the end of the year
M
wasn't expecting it to open at double the price but that's fine. this company sells 2 very successful products and they have HUGE demands for them. worth the 45 a stock buy in. it will be over 300 in 5 years.
A
what i got out of the call: procedure is super safe, super effective above anything else. replenishment product pipeline seems stable and established, increased due to new product introductions. european foothold established, especially in western europe. a pipeline of tangential new products can be expected to be released Q4 through the 1H of next year, in addition to flowsaver. TAM related to Covid induced clots was 11% in Q2 and decreasing from Q1, down to 4% recently, yet total TAM increased... which means (unfortunately) the significant Q3 spike we're seeing in Covid now is going to be on top of the increase in "normal"/target (non-Covid) procedures.
s
Wow!
This company must have multi-billion dollar product. MC=1.7 billion...
Talk about potential for growth...
Good Luck and do your due diligence always...
A
any news to account for a 12% drop?
K
You bet the high valuation is justified !!!
113% yoy revenue growth ... beats both top and bottom line ... 13c vs 5c and 57.4M vs 55M revs ... cash increased from $164M to $174M.
Full year guidance increased from 234M to 245M.
A
So, the company hit their target and has great prospects, of course the stock tanks? Do I not understand what this whole thing is about anymore?
$199!
They are profitable, they have 179 M cash and only 29 M debt.
Why this offering, they do not need money? It could be some acquisition.
Any second offering with intention to grow business is a wise decision.
- revenue 144% over last year
- 2x forecast for this year
- earnings crossed over to positive
- huge margins
+ entering new European market
+ 2 new products
I think we'll see $199 before the end of the year
procedure is super safe, super effective above anything else.
replenishment product pipeline seems stable and established, increased due to new product introductions.
european foothold established, especially in western europe.
a pipeline of tangential new products can be expected to be released Q4 through the 1H of next year, in addition to flowsaver.
TAM related to Covid induced clots was 11% in Q2 and decreasing from Q1, down to 4% recently, yet total TAM increased...
which means (unfortunately) the significant Q3 spike we're seeing in Covid now is going to be on top of the increase in "normal"/target (non-Covid) procedures.
This company must have multi-billion dollar product. MC=1.7 billion...
Talk about potential for growth...
Good Luck and do your due diligence always...
113% yoy revenue growth ... beats both top and bottom line ... 13c vs 5c and 57.4M vs 55M revs ... cash increased from $164M to $174M.
Full year guidance increased from 234M to 245M.